GH1 and Insulin resistance: A dose-related increase in insulin resistance was noted in patients treated with higher doses of recombinant GH (0.045 mg/kg/day vs 0.0675 mg/kg/day and 0.09 mg/kg/day), as evidenced by increased area under the curve (AUC) for insulin during OGTT, insulinogenic index, and urinary C-peptide (24).